Efficacy and safety of roflumilast taken in the morning or evening in patients with stable asthma (12 to 70 y) (BY217/M2-015)

Study identifier:BY217/M2-015

ClinicalTrials.gov identifier:NCT00163475

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

The MOVE-study: Morning versus evening administration of 500 mcg Roflumilast once daily for 6 weeks in patients with asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

511

Study type

Interventional

Age

12 Years - 70 Years

Date

Study Start Date: 01 May 2004
Primary Completion Date: 01 Aug 2005
Study Completion Date: 01 Aug 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria